Preferred Label : quinuclidines;

MeSH definition : A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.;

MeSH synonym : Quinuclidine;

Wikipedia link : https://en.wikipedia.org/wiki/Quinuclidines;

Is substance : O;

Details


Main resources

You can consult :

A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.

https://www.has-sante.fr/jcms/p_3191672/fr/laventair-ellipta
2020
false
false
false
France
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
vilanterol
Vilanterol Trifenatate
evaluation of the transparency committee
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes

---
https://www.has-sante.fr/jcms/p_3191675/fr/anoro-ellipta
2020
false
false
false
France
drug combinations
umeclidinium
vilanterol
vilanterol and umeclidinium bromide
evaluation of the transparency committee
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes

---
https://www.has-sante.fr/jcms/p_3224928/fr/akynzeo
2020
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
insurance, health, reimbursement
netupitant, palosentron drug combination
palonosetron, combinations
antiemetics
nausea
vomiting
antineoplastic agents
nausea
vomiting
adult
isoquinolines
pyridines
quinuclidines

---
https://www.has-sante.fr/portail/jcms/c_2964750/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
fluticasone furoate
fluticasone furoate
glucocorticoids
glucocorticoids
umeclidinium
umeclidinium
muscarinic antagonists
muscarinic antagonists
vilanterol
vilanterol
pulmonary disease, chronic obstructive
product surveillance, postmarketing
vilanterol, umeclidinium bromide and fluticasone furoate
administration, inhalation
adult
aged
drug interactions
pregnancy
breast feeding
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines
androstadienes
androstadienes
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes

---
https://www.has-sante.fr/portail/jcms/c_2964753/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines

---
https://www.has-sante.fr/portail/jcms/c_2847883/fr/elebrato-trelegy-ellipta
2018
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines

---
Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Elebrato-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes

---
Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Trelegy-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes

---
http://www.cochrane.org/fr/CD011897/les-inhalateurs-contenant-du-bromure-dumeclidinium-sont-ils-efficaces-et-surs-pour-le-traitement-des
2017
false
false
false
France
United Kingdom
French
french abstract
pulmonary disease, chronic obstructive
administration, inhalation
GSK573719
quinuclidines
quinuclidines
GSK573719
review of literature

---
http://www.has-sante.fr/portail/jcms/c_2754746/fr/laventair
2017
false
false
false
France
French
treatment outcome
umeclidinium
vilanterol
vilanterol and umeclidinium bromide
drug combinations
administration, inhalation
bronchodilator agents
pulmonary disease, chronic obstructive
adult
muscarinic antagonists
adrenergic beta-2 receptor agonists
evaluation of the transparency committee
insurance, health, reimbursement
GSK573719
benzyl alcohols
chlorobenzenes
quinuclidines

---
http://www.has-sante.fr/portail/jcms/c_2755488/fr/akynzeo
https://www.has-sante.fr/portail/jcms/c_2755488/fr/akynzeo-palonosetron-netupitant-setron-en-association
2017
false
false
false
France
French
treatment outcome
drug combinations
netupitant
palonosetron, combinations
palonosetron hydrochloride
nausea
nausea
antineoplastic agents
vomiting
vomiting
administration, oral
serotonin 5-HT3 receptor antagonists
Neurokinin-1 receptor antagonists
netupitant, palosentron drug combination
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
pyridines
isoquinolines
quinuclidines
Palonosetron

---
https://www.ema.europa.eu/medicines/human/EPAR/Rolufta
2017
false
false
false
United Kingdom
French
English
adult
pulmonary disease, chronic obstructive
package leaflet
syndication feed
drug evaluation
summary of product characteristics
umeclidinium
umeclidinium
drug approval
europe
treatment outcome
umeclidinium bromide
administration, inhalation
muscarinic antagonists
muscarinic antagonists
drug interactions
pregnancy
breast feeding
clinical trials, phase iii as topic
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines

---
http://www.has-sante.fr/portail/jcms/c_2658513/fr/palonosetron-accord
2016
false
false
false
France
French
evaluation of the transparency committee
drugs, generic
palonosetron
Palonosetron 0.25mg/5mL injection solution 5mL vial (product)
palonosetron hydrochloride
isoquinolines
quinuclidines
Palonosetron

---
https://www.ema.europa.eu/medicines/human/EPAR/palonosetron-accord
2016
false
United Kingdom
English
French
syndication feed
chemotherapy-induced nausea and vomiting
treatment outcome
drugs, generic
drug approval
europe
vomiting
nausea
vomiting
nausea
isoquinolines
quinuclidines
palonosetron
serotonin 5-HT3 receptor antagonists
serotonin 5-HT3 receptor antagonists
drug evaluation
package leaflet
summary of product characteristics
isoquinolines
quinuclidines
Palonosetron 0.25mg/5mL injection solution 5mL vial (product)
Palonosetron
Palonosetron

---
https://www.ema.europa.eu/medicines/human/EPAR/palonosetron-hospira
2016
false
United Kingdom
English
French
syndication feed
treatment outcome
chemotherapy-induced nausea and vomiting
drugs, generic
vomiting
nausea
vomiting
nausea
isoquinolines
quinuclidines
palonosetron
serotonin 5-HT3 receptor antagonists
serotonin 5-HT3 receptor antagonists
drug evaluation
package leaflet
summary of product characteristics
isoquinolines
quinuclidines
Palonosetron 0.25mg/5mL injection solution 5mL vial (product)
Palonosetron
Palonosetron

---
http://www.has-sante.fr/portail/jcms/c_2609211/fr/aloxi
http://www.has-sante.fr/portail/jcms/c_2609211/fr/aloxi-palonosetron-antiemetique-injectable
2016
false
France
French
infant
acute disease
chemotherapy-induced nausea and vomiting
guidelines for drug use
isoquinolines
quinuclidines
injections
nausea
vomiting
antiemetics
nausea
vomiting
antineoplastic agents
palonosetron
serotonin 5-HT3 receptor antagonists
evaluation of the transparency committee
Palonosetron 0.25mg/5mL injection solution 5mL vial (product)
Palonosetron

---
http://www.has-sante.fr/portail/jcms/c_2606854/fr/incruse
2016
false
false
false
France
French
adult
pulmonary disease, chronic obstructive
umeclidinium
umeclidinium
treatment outcome
umeclidinium bromide
administration, inhalation
muscarinic antagonists
muscarinic antagonists
bronchodilator agents
bronchodilator agents
evaluation of the transparency committee
GSK573719
GSK573719
quinuclidines
quinuclidines

---
http://www.has-sante.fr/portail/jcms/c_2676741/fr/anoro
http://www.has-sante.fr/portail/jcms/c_2676741/fr/anoro-bromure-d-umeclidinium-/-vilanterol-anticholinergique-/-agoniste-beta2-adrenergique-de-longue-duree-d-action
2016
false
false
false
France
French
evaluation of the transparency committee
drug combinations
vilanterol and umeclidinium bromide
insurance, health, reimbursement
treatment outcome
pulmonary disease, chronic obstructive
adult
bronchodilator agents
guidelines for drug use
vilanterol
umeclidinium
vilanterol trifenatate
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes

---
https://www.ema.europa.eu/medicines/human/EPAR/Akynzeo
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
netupitant
netupitant
palonosetron, combinations
palonosetron hydrochloride
palonosetron hydrochloride
Drug-Related side effects and adverse reactions
nausea
nausea
antineoplastic agents
vomiting
vomiting
administration, oral
serotonin 5-HT3 receptor antagonists
serotonin 5-HT3 receptor antagonists
Neurokinin-1 receptor antagonists
Neurokinin-1 receptor antagonists
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
netupitant, palosentron drug combination
netupitant, palosentron drug combination
pyridines
pyridines
isoquinolines
quinuclidines
isoquinolines
quinuclidines
Palonosetron
Palonosetron

---
https://www.ema.europa.eu/medicines/human/EPAR/Anoro
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
umeclidinium
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
drug monitoring
product surveillance, postmarketing
drug approval
europe
administration, inhalation
bronchodilator agents
bronchodilator agents
pulmonary disease, chronic obstructive
adult
aged
drug interactions
pregnancy
breast feeding
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials as topic
drug evaluation, preclinical
drug evaluation
GSK573719
GSK573719
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
quinuclidines
quinuclidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Laventair
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
umeclidinium
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
drug monitoring
product surveillance, postmarketing
drug approval
europe
administration, inhalation
bronchodilator agents
bronchodilator agents
pulmonary disease, chronic obstructive
adult
aged
drug interactions
pregnancy
breast feeding
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials as topic
drug evaluation, preclinical
GSK573719
GSK573719
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
quinuclidines
quinuclidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Incruse
2014
false
false
false
United Kingdom
French
English
adult
pulmonary disease, chronic obstructive
package leaflet
syndication feed
drug evaluation
summary of product characteristics
umeclidinium
umeclidinium
drug approval
europe
treatment outcome
umeclidinium bromide
administration, inhalation
muscarinic antagonists
muscarinic antagonists
drug interactions
pregnancy
breast feeding
clinical trials, phase iii as topic
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines

---
Summary Basis of Decision (SBD) for Anoro Ellipta
Umeclidinium bromide and vilanterol trifenatate 62.5 µg of umeclidinium (as umeclidinium bromide) and 25 µg of vilanterol (as vilanterol trifenatate) Powder, oral inhalation
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00270
2014
false
false
false
Canada
French
English
summary of product characteristics
drug approval
canada
drug combinations
administration, inhalation
treatment outcome
drug evaluation
risk assessment
clinical trials as topic
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
umeclidinium
bronchodilator agents
bronchodilator agents
Delayed-Action preparations
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
pulmonary disease, chronic obstructive
bronchitis, chronic
pulmonary emphysema
adult
aged
GSK573719
GSK573719
quinuclidines
quinuclidines
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes

---
https://www.ema.europa.eu/medicines/human/EPAR/Aloxi
2012
false
United Kingdom
English
French
syndication feed
chemotherapy-induced nausea and vomiting
vomiting
nausea
vomiting
nausea
isoquinolines
quinuclidines
palonosetron
serotonin 5-HT3 receptor antagonists
serotonin 5-HT3 receptor antagonists
drug evaluation
package leaflet
summary of product characteristics
isoquinolines
quinuclidines
Palonosetron 0.25mg/5mL injection solution 5mL vial (product)
Palonosetron
Palonosetron

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00004
2012
false
false
false
Canada
Product containing palonosetron (medicinal product)
palonosetron
drug information
isoquinolines
quinuclidines
Palonosetron

---
http://www.has-sante.fr/portail/display.jsp?id=c_487092
2007
false
France
French
isoquinolines
quinuclidines
injections
nausea
vomiting
antiemetics
nausea
vomiting
antineoplastic agents
palonosetron
isoquinolines
quinuclidines
serotonin 5-HT3 receptor antagonists
evaluation of the transparency committee
Palonosetron 0.25mg/5mL injection solution 5mL vial (product)
Palonosetron

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.